Edward J. Borkowski, Former CFO of Mylan, N.V. Joins Transdermal Delivery Solutions Board of Directors

Transdermal Delivery Solutions, a leader in the development of
breakthrough spray-on drug delivery systems, announced today that Edward
J. Borkowski has joined its Board of Directors

PALM BEACH GARDENS, Fla.–(BUSINESS WIRE)–Transdermal Delivery Solutions Corporation (TDSC) www.TDSC.us
announced today that pharmaceutical entrepreneur Edward J. Borkowski
has joined its Board of Directors as Chair of the Audit Committee.
Borkowski (https://www.linkedin.com/in/edward-j-borkowski-00b22631
) has held the title of Chief Financial Officer for a myriad of
multi-billion dollar healthcare organizations such as Mylan, Inc. ($5.5B)
(NASDAQ: MYL), Carefusion Corporation ($3.5B), ConvaTec ($1.7B), and
is currently CFO at Amerigen Pharmaceuticals, an early stage, private,
generic pharmaceutical company.

“We are very pleased to have Ed Borkowski, a veteran industry
professional, join our Board of Directors. His years of experience as
CFO of Mylan, N.V., as well as his reputation, relationships and
track-record of success in the pharmaceutical industry, will be an
invaluable asset to our organization,” said Kenneth Kirby, President of
TDSC.

During Borkowski’s seven-year tenure at Mylan, he led the company from a
$900 million revenue U.S.-based firm, to one of the world leaders in
generic pharmaceuticals through a series of strategic acquisitions and
internally focused development of new products; it is now $5.5 billion
in revenue. At CareFusion Corporation, Borkowski was tasked with taking
the company public in 2010. CareFusion is now a global $3.5 billion
revenue healthcare company focused on pharmaceutical dispensing
equipment, infusion pumps, ventilators and surgical instruments.
Borkowski was acting CFO at ConvaTec through 2013. It is now is a $1.7
billion revenue global healthcare company, private-equity owned and
focused on Ostomy, wound care, surgical dressings and urology and
incontinence related products.

“I am thrilled to join TDSC and look forward to helping take this
paradigm-shifting platform technology to the market,” said Edward J.
Borkowski. “We have the potential to create a new standard of care in
drug delivery that will improve the quality of life for whole classes of
patients that struggle with pills – including children and the elderly.”

About Transdermal Delivery Solutions (TDSC)

TDSC is committed to advancing the science of transdermal drug delivery
using its patented spray-on delivery system platform. TDSC’s proprietary
system enables a much larger number of medications to be delivered
directly through the skin, for systemic or localized application,
utilizing its rapid acting, patchless, spray-on technology. TDSC’s
technology represents a paradigm-shift in drug delivery. http://www.tdsc.us/lower.php?url=tdsc-platform

Transdermal Delivery Solutions Corp.

Contact Information:

Name: Cindy Metzler, MarCom Consultant (for TDSC)

Email: cindy@cindymetzler.com

Web: www.tdsc.us

Address: 10384 Riverside Drive, Palm Beach Gardens, FL 33410 USA

Telephone: 561.429.6429 (Headquarters)

Contacts

MarCom Consultant (for TDSC)
Cindy Metzler, 561-429-6429
Email:
cindy@cindymetzler.com
Web:
www.tdsc.us